Breast Cancer Track
High Risk Breast Cancer:
Diagnosis and Management of Patients with Hereditary Cancers
Judy E. Garber, MD, MPH
Treating Breast Cancer Subtypes:
Current and Emerging Evidence in HER2+, Triple Negative, and Other Subtypes
Eric P. Winer, MD
Hormone Receptor Positive Breast Cancer:
Initial Treatment and Long Term Management Choices
Harold J. Burstein, MD, PhD
Breast Cancer Survivorship:
Strategies That Promote Health and Quality of Life in Breast Cancer Patients After Treatment is Finished
Ann H. Partridge, MD, MPH
Supportive Care Track
Sarcomas and GIST:
Current Management and a Look Towards the Future
George D. Demetri, MD
Gastrointestinal Cancer Track
Esophageal, Gastric and Pancreatic Cancers:
How to Improve Survival for These Deadly Cancers
Peter C. Enzinger, MD
Familial Gastrointestinal Cancers:
Personalized Strategies for Diagnosis and Management
Sapna Syngal, MD, MPH
Preventing the Development and the Recurrence of Gastrointestinal Cancers through Lifestyle Practices:
Recent and Emerging Clinical Data
Charles S. Fuchs, MD, MPH
Adjuvant and Metastatic Colon Cancer:
Evidence-Based Therapeutic Choices
Robert J. Mayer, MD
Genitourinary Cancers Track
Advanced and Metastatic Prostate Cancer:
Emerging Therapeutic Approaches
Philip W. Kantoff, MD
Bladder and Renal Cancer:
Integrating New Therapies into Current Best Practices
Robert Dreicer, MD
|
Head, Neck and Lung Cancers Track
Head and Neck Cancer:
Changing Epidemiology and Evolving Interdisciplinary Management
Robert I. Haddad, MD
Non-Small Cell Lung Cancer:
Current and Emerging First Line Approaches
Pasi A. Jänne, MD, PhD
Selected Topics in Lung Cancer:
Second Line Non-Small Cell Lung Cancer and Advances in Small Cell Lung Cancer and Mesothelioma
Bruce E. Johnson, MD
Melanomas Cancer Track
Melanoma:
Recent Advances and Emerging Clinical Data
F. Steven Hodi Jr., MD
Hematologic Malignancies Track
Lymphomas:
Current and Emerging Therapies for Non-Hodgkins and Hodgkins Lymphomas
Arnold S. Freedman, MD
Myeloid Malignancies:
Evidence-Based Best Practices for Molecular Testing, Risk Assessment, and Therapeutic Management
Daniel J. DeAngelo, MD, PhD
Myeloproliferative Disorders:
Diagnosis, Risk Assessment, and Evolving Management Strategies
Ayalew Tefferi, MD
Multiple Myeloma:
Novel Treatment Strategies in Multiple Myeloma
Kenneth C. Anderson, MD
Chronic Lymphocytic Leukemia:
Best Practices for Assessing Risk and Integrating Current and Emerging Therapeutic Approaches
John C. Byrd, MD
|